Skip to main content

Cannabis Is a Budding Strategy Against Ovarian Cancer

A combination of two cannabis-derived compounds can target ovarian cancer cells while sparing healthy cells, offering early clues toward new treatment possibilities.

Written byLaura Tran, PhD
| 2 min read
Image of marijuana buds surrounding a small jar of cannabis oil.
Register for free to listen to this article
Listen with Speechify
0:00
2:00

When it comes to treating ovarian cancer, existing drugs are often limited in effectiveness and can cause significant side effects, underscoring the need for new options. In response, researchers are exploring alternative drugs, including herbal-based strategies.

For instance, a research group from Khon Kaen University investigated the cannabis plant, which has been used to help relieve side effects of cancer treatments. Namely, they focused on the individual and combined effects of two cannabis compounds on human ovarian cancer cell lines: cannabidiol (CBD), which is non-psychoactive, and delta-9-tetrahydrocannabinol (THC), which is responsible for cannabis’s psychoactive effects and “high” feeling.

In a recent study, published in Frontiers in Pharmacology, the same research group demonstrated that a combination of CBD and THC successfully killed a large proportion of ovarian cancer cells while sparing healthy cells in vitro.1 Their findings lay a foundation for alternative treatments.

First, the researchers assessed two ovarian cancer cell lines: one that is sensitive to platinum-derived drugs and another that is resistant. Platinum drugs are often used as initial ovarian cancer treatments. They treated these groups and healthy cells with different doses of CBD, THC, and ratios of CBD:THC.

Of these treatments, the CBD:THC combination at a one-to-one ratio had a synergistic effect, producing the best results: It led to in fewer and smaller cancer cell colonies, induced cell death, and decreased the cells’ ability to migrate. The researchers also noted that the treatment exhibited selective toxicity towards cancer cells, leaving healthy cells unharmed.

Continue reading below...

Like this story? Sign up for FREE Cancer updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

To better understand the mechanisms behind these anti-cancer effects, the researchers examined key cell signaling pathways. In ovarian cancer cells, the PI3K/AKT/mTOR signaling pathway is often hyperactivated, regulated by phosphorylation, and contributes to tumor development. When the team tested the CBD:THC combination on ovarian cancer cell lines, they observed reduced phosphorylation of proteins within the PI3K/AKT/mTOR pathway. They also detected an increase, or restoration, of a tumor-suppressor protein, which may further contribute to the dampened signaling activity.

“Although our study is still preliminary, it lays an important foundation for future research into the potential applications of CBD and THC in ovarian cancer treatment,” said study coauthor Siyao Tong in a press release.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Laura Tran, PhD

    Laura Tran is an Associate Editor, Content & Newsletters at The Scientist. She has a background in microbiology. Laura earned her PhD in integrated biomedical sciences from Rush University, studying how circadian rhythms and alcohol impact the gut. While completing her studies, she wrote for the Chicago Council on Science and Technology and participated in ComSciCon Chicago in 2022. In 2023, Laura became a science communication fellow with OMSI, continuing her passion for accessible science storytelling.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo